1 / 43

HIV/AIDS BOARD REVIEW Harold Henderson, MD

HIV/AIDS BOARD REVIEW Harold Henderson, MD. Diagnosis Natural History Clinical Manifestations Drug Therapy, Toxicity, Interactions Opportunistic Infections-diagnosis, treatment, prophylaxis. Sample Test Question.

gary-delaney
Download Presentation

HIV/AIDS BOARD REVIEW Harold Henderson, MD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIV/AIDS BOARD REVIEWHarold Henderson, MD • Diagnosis • Natural History • Clinical Manifestations • Drug Therapy, Toxicity, Interactions • Opportunistic Infections-diagnosis, treatment, prophylaxis

  2. Sample Test Question • A 57 y/o healthy adult female with hypertension and diabetes comes to your office for a routine followup appointment. She takes HCTZ and follows an ADA diet for her diabetes. She feels well and has no complaints. She received the influenza vaccine from MSDH 3 days ago. You order HIV serology for routine screening, and the result is a positive EIA but an indeterminate Western Blot. The best explanation for this result is: • chronic asymptomatic HIV infection • acute HIV infection • lab error • false positive EIA related to the influenza vaccine

  3. DIAGNOSIS • EIA-sensitivity/specificity 99%; antibodies usually detectable within 2-6 weeks of acute infection; virtually 100% reactivity by 6 months • Needs to be confirmed with Western Blot or IFA; indeterminate results may be due to acute infection period • Causes of false negative EIA-acute infection (“window” period) • Causes of false positive EIA-hematologic malignancies, autoimmune disorders (SLE), + RPR, influenza and Hep B vaccination • Other tests: oral (rapid) test; home test; p24 antigen (may be detectable early in acute infection but <50%); PCR-can be used but false positive and negative rates are too high as screening tool • Neonatal diagnosis-maternal antibodies cross placenta and may be detectable for >one year, PCR is test of choice

  4. Sample Test Question • A 23 y/o male is evaluated in the ER with fever-101°, nausea, malaise and a diffuse, erythematousmaculopapular rash for about 3 days. He denies the use of IV drugs but has multiple sexual partners and says “I usually use condoms.” He lives in Jackson and works at a local Target, has always been healthy and takes no meds. PE is normal except for painless, bilateral, 1x2 cm cervical adenopathy. Labs are unremarkable except for a platelet count of 77,000. The best diagnostic test to order is: • HIV serology • HIV p24 antigen • PCR HIV quantitative (viral load) • measles serology

  5. ACUTE HIV INFECTION SYNDROME • Common signs/symptoms (>50%)-fever, adenopathy, pharyngitis, rash (erythematous maculopapular), myalgias • Less common-headache, nausea/vomiting, hepatosplenomegaly, weight loss, thrush, neurologic symptoms (aseptic meningitis, meningoencephalitis, Guillain-Barre syndrome), thrombocytopenia • EIA usually negative, PCR is test of choice

  6. Sample Test Question • A 30 y/o HIV+ male is followed by you as his primary care provider. He is asymptomatic and feels well, has a full time job. Lab results (on two separate occasions) include CD4 counts-576 & 553, and viral loads-36,000 & 59,000. He is interested in starting HAART if you recommend it. Which of the following is the best treatment plan? • Start tenofovir/emtricitabine/efavirenz (Atripla). • Delay starting HAART, and follow with repeat CD4s and viral loads every 3-4 months. • Start zidovudine/lamivudine (Combivir). • Start trimethoprim/sulfamethoxazole as PCP prophylaxis, and follow every 3-4 months.

  7. Antiviral Therapy- When to Start HAART Status Recommendation Symptomatic HIV Start therapy for all disease patients Asymptomatic Start therapy CD4<500 Asymptomatic CD4 > 500 Start therapy

  8. Anti-HIV Drug Regimens • Minimum number of active drugs is three per combination • Usually two NRTIs and one NNRTI (such as AZT/lamivudine/efavirenz) or two NRTs and one protease inhibitor (such as abacavir/lamivudine/lopinavir-ritonavir) • PI boosting with ritonavir-commonly done to increase levels of the PI; ritonavir does not count as an antiviral drug in the combination; example: AZT, lamivudine, atazanavir/ritonavir is a 3-drug combination • Resistance testing used to help choose initial regimen and to guide salvage regimens after drug failure

  9. Current ARV Medications * EVG currently available only in coformulation with cobicistat (COBI)/ TDF/FTC www.aidsetc.org

  10. Preferred HAART Regimens for Initial Therapy • Tenofovir/emtricitabine/efavirenz (Atripla) • Tenofovir/emtricitabine/atazanavir/ritonavir • Tenofovir/emtricitabine/darunavir/ritonavir • Tenofivir/emtricitabine/raltegravir • Tenofovir/emtricitabine/elvitegravir/cobicistat • Tenofovir/emtricitabine/dolutegravir • Abacavir/emtricitabine/dolutegravir

  11. Sample Test Question • A 24 y/o HIV positive female, 15 weeks pregnant, is referred to you for medical therapy by her obstetrician, who plans to manage her pregnancy but is not familiar with HIV care. She was recently diagnosed, is asymptomatic, has no other significant past medical history and takes no medications. Lab results include a CD4-535 and a viral load-26,000. An HIV drug susceptibility test shows no drug resistance. Regarding HIV care during her pregnancy, the following is the best plan: • She is asymptomatic with a good CD4 count, HAART is not indicated. • Start zidovudine (AZT) 300 mg BID. • Start tenofovir/emtricitabine/efavirenz (Atripla) • Start zidovudine/lamuvidine (Combivir) and lopinavir/ritonavir (Kaletra)

  12. HIV and Pregnancy • Perinatal transmission of HIV is absence of HAART is 20-30% • HAART decreases transmission to <2-3%, all pregnant HIV-infected women should be on HAART after the first trimester • Do not use efavirenz-?teratogenic

  13. Sample Test Question • A 25 y/o male with AIDS (he is asymptomatic but has a CD4 count-153, viral load-49,900) is started on zidovudine/lamivudine (Combivir) and efavirenz (Sustiva) as HAART, and TMP/SMZ (Bactrim) SS-one tablet daily as PCP prophylaxis. He returns for followup 8 weeks later. He has no complaints except for very pronounced fatigue for the past two weeks. Lab findings now include a Hct-21 (decreased from 34 six weeks ago), MCV-107, WBC-3.9, a platelet count of 149,000, viral load-undetectable, and a negative FOBT. The following is the best treatment plan: • Zidovudine should be stopped, another NRTI should be started in its place, and he should receive a blood transfusion. • TMP/SMZ should be stopped, monthly aerosolized pentamidine should be started, and he should receive a blood transfusion. • The same medications are continued, and he should receive a blood transfusion. • Blood should be obtained for B12 and folate levels, and then he should receive a blood transfusion.

  14. Individual NRTI Toxicity-Hematologic • AZT-anemia and/or neutropenia • Typically early (2-6 weeks), but may occur later in course of therapy • May be severe • More common in advanced disease with pre-existing bone marrow suppression • Generally resolves with drug discontinuation, but resolution may be quite slow

  15. NRTI-Hypersensitivity • Abacavir, up to 5% incidence • Generally occurs within first 8 weeks • Characterized by fever, fatigue, nausea, maculopapular rash, with myalgias, cough and dyspnea less common • Symptoms occur over several days, and may increase with each dose • Predicted by HLA B5701 haplotype • Treatment-discontinue the drug • Rechallenge may be life-threatening

  16. NRTI-Nephrotoxicity • Tenofovir may cause proximal renal tubular dysfunction • Occasional decrease in creatinine clearance • Toxicity is usually mild (average increase in creatinine 0.15) and does not require drug discontinuation • Severe nephrotoxicity uncommon (<5%) but does happen • Avoid use in patients with pre-existing renal dysfunction • ?Use in diabetics and hypertensives

  17. Sample Test Question • A 37 y/o HIV infected male is admitted from the ER with nausea, vomiting and abdominal pain for 3 days. HIV infection was diagnosed two years ago. He has no other illnesses, has never had an AIDS-defining illness, and on his most recent clinic followup visit one month ago his viral load was undetectable and his CD4 count was 415. He drinks a glass of wine “occasionally” and does not smoke. His medications are tenofovir 300mg qday, didanosine 400mg qday, atazanavir 300mg qday, and ritonavir 100mg qday. Physical exam findings include orthostatic hypotension and diffuse epigastric tenderness. Lab results include a lipase-1163, ALT-177, AST-129, and normal bilirubin. Which of the following statements is best regarding his condition? • He has tenofovir-induced pancreatitis. • He has alcohol-induced pancreatitis. • He has HIV enteropathy. • He has didanosine-induced pancreatitis.

  18. NRTI-GI Toxicity • Pancreatitis-didanosine, uncommon (0.5-5%) but potentially serious; be aware of interaction between ddI and tenofovir (dose of ddI needs adjusting) • Hepatotoxicity 1) Mitochondrial toxicity with hepatic steatosis-AZT, stavudine, didanosine 2) Abacavir hypersensitivity 3) Hepatitis B flares-withdrawal or development of resistance to tenofovir, lamivudine, or emtricitabine

  19. Test Question • A 30 y/o HIV positive male has been on tenofovir/emtricitabine/ indinavir/ritonavir for 14 months. He has never had any other medical problems. He has been asymptomatic, his viral load has gone from its baseline of 114,000 to undetectable and his CD4 count has increased from 258 to 433. He now c/o nausea, right flank pain and gross hematuria for two days, no fever. He had normal baseline renal function, but labs now show WBC-6.1, BUN-37 and creatinine-2.2. Urinalysis shows hematuria. The following is the best statement about his condition: • He most likely has HIV-induced renal failure and should be referred to a nephrologist. • He has tenofovir-induced nephrotoxicity, and the drug should be stopped. • He has indinavir-induced nephrotoxicity due to nephrolithiasis, and the drug should be stopped. • He most likely has a urinary tract infection. His HAART meds should be continued, and he should be started on empiric antibiotics pending results of a urine culture.

  20. TOXICITY-INDIVIDUAL PROTEASE INHIBITORS • Indinavir (Crixivan)-nausea, diarrhea, nephrolithisis/nephrotoxicity in 10-20% • Ritonavir (Norvir)-nausea, diarrhea, circumoralparesthesias 5-10% • Nelfinavir (Viracept)-diarrhea • Kaletra, fosamprenavir (Lexiva), tipranavir (Aptivus)-GI intolerance • atazanavir (Retataz)-increased indirect bilirubin, nephrolithiasis (uncommon)

  21. Sample Test Question • A 33 y/o HIV positive female has been in good health on HAART (stavudine/lamivudine/lopinavir/ritonavir) for three years. Her most recent CD4 is 345 with an undetectable viral load 8 weeks ago. However she now complains of has 3 weeks of worsening fatigue, anorexia, and nausea, and she has lost 12 lbs during that time. Physical exam is unremarkable. Initial lab results include an AST-111, ALT-128, total bilirubin-0.8, lipase-126, Na-138, K-3.8, Cl-102, CO2-16, BUN-24, creatinine-1.4 and a normal CBC. The best diagnostic test(s) at this time is: • CT of the abdomen/pelvis • CK and aldolase levels • Arterial Blood Gases • lactic acid level

  22. Lactic Acidosis Syndrome • Symptomatic disease uncommon, 0.5-1/100 patient years of NRTI exposure • Most strongly associated with d4T(stavudine) and d4T/ddI use; other risk factors are pregnancy, ddI (didanosine) with ribavirin or hydroxyurea • Non-specific symptoms: fatigue, nausea, vomiting, diarrhea, abdominal discomfort or distention; hepatic steatosis • Higher lactic acid levels (>10mM) have worse prognosis • Therapy: stop “d” drug, supportive care, ?vitamins • No value to monitor lactic acid in absence of symptoms

  23. Sample Test Question • A 35 y/o male with AIDS (last CD4-97) is in your care. He also has peripheral neuropathy and hyperlipidemia. His medications are tenofovir/emtricitabine/efavirenz (Atripla), TMP/SMZ (Bactrim), simvastatin, and gabapentin. He now c/o myalgias, anorexia and fatigue for two weeks. Lab results include total cholesterol-235, LDL-161, AST-205, ALT 187, and CK-851. The best plan at this time is: • Increase simvastatin dose for better treatment of his hyperlipidemia. • Stop simvastatin because on interaction with efavirenz is causing drug toxicity. • Stop tenofovir because of tenofovir-related hepatotoxicity. • Stop tenofovir because of tenofovir-related myopathy.

  24. Drug Interactions and Anti-HIV Agents Lipid-lowering agents (statins) • PIs, efavirenz (statin) • use pravastatin or rosuvastatin (minimal) or atorvastatin (moderate) Anticonvulsants • phenytoin, carbamazepine, phenobarbital-monitor levels • most PIs Miscellaneous • methadone-some PIs, nevirapine, efavirenz • sildenafil, vardenafil-most PIs • warfarin-most PIs, efavirenz

  25. Drug Interactions and Anti-HIV Agents Antifungals • itraconazole-most PIs ( itra), nevirapine and efavirenz ( itra) • voriconazole-ritonavir, efavirenz ( vori) Antimycobacterials • rifampin-all PIs, nevirapine, • rifabutin-all PIs, nevirapine, efavirenz (but <rifampin) • clarithromycin-most PIs, nevirapine, efavirenz Oral contraceptives • most PIs, nevirapine, efavirenz

  26. PCP (Pneumocystis jiroveci)-Clinical features • Usually a CD4 < 200, co-existent thrush common • Sub-acute presentation (weeks) • Common symptoms-fever, weight loss, progressive DOE, cough • Hypoxemia • CXR-bilateral, interstitial infiltrates most common; normal, pneumothorax less common • Diagnosis-induced sputum (poorly sensitive), BAL >95% sensitivity; LDH and galactomannan may also be useful

  27. PCP-Treatment • Preferred-Trimethoprim/sulfamethoxazole 15-20 mg/kg/day in 3-4 divided doses IV or oral (Bactrim DS two tabs TID PO) • Hypoxemia-use steroids if room air PO <70mm or A-a gradient >35mm • Response to therapy may be slow (5-7 days) • Alternatives: • trimethoprim/dapsone • pentamidine IV • clindamycin/primaquine • atovoquone

  28. Tuberculosis • Much more common in setting of HIV disease • May have typical pulmonary TB at higher CD4 counts, atypical presentation very common at CD4 <100-extrapulmonary/disseminated TB and CXR may show infiltrates or miliary pattern without cavitation • Diagnosis with AFB smears/culture/biopsy • High false-negative rate with PPD • Treatment-4 anti-TB drugs to start; beware of rifampin and drug interactions • Response to therapy similar to HIV negative persons

  29. OPPORTUNISTIC INFECTION QUESTION • A 36 y/o HIV infected male, CD4-33, is brought to the ER with 5 days of fever and headache. He has not been in care for more than one year and is taking no meds. He is lethargic on exam and has white patches on his tongue and buccal mucosa. An MRI of the head shows focal, enhancing lesions with surrounding edema-2 in right parietal lobe and one in left basal ganglia. The best evaluation/treatment plan is: • Obtain an LP to evaluate for cryptococcal meningitis. • start pyrimethamine and sulfadiazine • consult neurosurgery for brain biopsy • start HAART as therapy for AIDS-related PML

  30. CNS TOXOPLASMOSIS • Most common cause of brain abscess • CD4 usually <100 • Common presentation-fever, headache, altered mental status, focal neurologic deficits, seizure • Diagnosis: Toxo serology positive in 95%; CNS imaging usually shows multiple, bilateral, ring-enhancing lesions; single lesions may be confused with lymphoma • Treatment: pyrimethamine/sulfadiazine  leucovorin, dexamethasone for mass effect due to edema; alternatives include pyrimethamine/clindamycin and Bactrim • Clinical and/or radiographic improvement in 1-2 weeks

  31. CRYPTOCOCCAL MENINGITIS • Most common cause of meningitis • Extra-meningeal disease less common, sometimes with papular skin lesions • CD4 usually <100 • Usual presentation-subacute with fever, headache, altered mental status, seizure • Diagnosis-CSF crypto antigen, culture, India Ink smear; blood cultures; serum CAG positive in >95% • Treatment-initial (7-14 days) period of amphotericin with flucytosine, followed by fluconazole 400 mg qday x 8 weeks, then  to 200 mg qday • Elevated intracranial pressure-common, important cause of morbidity and mortality; treat with serial LPs or VP shunt

  32. CMV DISEASE • Retinitis most common, CD4 usually <50 • Common presentation-floaters, visual field defect, loss of visual acuity • Diagnosis via funduscopic exam by ophthalmologist • Treatment: valgancyclovir 900 mg BID P0 x 14-21 days (systemic therapy required) with or without intraocular gancyclovir implant; alternatives include gancyclovir, foscarnet, and cidofovir; avoid AZT • CMV GI disease: usually esophagitis or colitis, biopsy for diagnosis, treat with valgancyclovir • CMV neurologic disease: • encephalitis: lethargy, confusion, fever; dx-CMV PCR of CSF • radiculopathy: rapidly progressive leg paresis, bowel and bladder dysfunction

  33. PML-Polymorphonuclear Leukoencephalopathy • Caused by JC viral infection of CNS • CD4 usually <200 • Common presentation-progressive cognitive and motor dysfunction over weeks to months; no fever • MRI of head shows hypodense lesions of white matter; CT not as sensitive • Diagnosis: compatible clinical syndrome and imaging study with positive JC viral PCR of CSF (sensitivity-80%); also brain biopsy • Treatment-HAART; no effective direct treatment known

  34. Candidiasis and HIV Infection • Oral candidiasis-very common, CD4 usually <300; can be treated with local or systemic antifungal therapy; avoid chronic, daily use of azoles • Esophageal candidiasis • thrush usually present, CD4 usually <100 • Symptoms: dysphagia, usually no fever; odynophagia suggests esophageal ulceration • Treatment: fluconazole 200 mg daily for 14-21 days, response usually within 7 days • Alternatives for fluconazole-refractory disease include itraconazole elixir PO, IV amphotericin B or IV caspofungin

  35. DISSEMINATED MAC-MYCOBACTERIUM AVIUM COMPLEX • Usually CD4 <50 • Typical presentation-subacute fever, night sweats, weight loss, diarrhea, anemia and neutropenia • Diagnosis via culture from blood or visceral organ; positive MAC cultures of sputum or stool document colonization only • Treatment • HAART • clarithromycin plus ethambutol plus/minus rifabutin, prolonged therapy necessary • watch for clarithromycin or rifabutin drug interactions

  36. DISSEMINATED HISTOPLASMOSIS • CD4 usually <200 • Common symptoms include fever (may be up to 105°), fatigue, weight loss, nausea and diarrhea • Multiorgan disease with lung, CNS, GI tract, liver, or bone marrow involvement • Diagnosis-cultures of blood or BM, visualization of organisms in peripheral blood or BM biopsy, urine Histo antigen (>90% sensitive) • Treatment: • severe disease: amphotericin B initially, followed by itraconazole • mild to moderate disease: itraconazole 200 mg BID x 8-12 weeks, then  to 100 mg BID as maintenance

  37. HERPES SIMPLEX • Any CD4 count • Orolabial and genital ulcerative lesions common; with advanced AIDS lesions may be more extensive, and may disseminate • Disease tends to be more extensive and refractory to therapy in AIDS • Treatment: • acyclovir 400 mg TID for 7-10 days for typical lesions, famcyclovir or valacyclovir also effective • Severe disease: may need IV therapy initially, more prolonged course • acyclovir-resistant disease-foscarnet IV or cidofovir IV • visceral organ involvement/encephalitis-high-dose acyclovir IV • chronic suppressive therapy for frequent recurrences or advanced AIDS

  38. HIV-RELATED MALIGNANCIES • Kaposi’s sarcoma-caused by HHV-8, CD4 usually <300, brown/violaceous skin macules/nodules, may cause visceral organ involvement, much less common in HAART era • Cervical cancer-associated with HPV, regular screening PAP smears in women recommended to monitor for dysplasia • Non-Hodgkin’s Lymphoma-CD4 usually <100, associated with EBV, often high-grade, multiple presentations possible including primary effusion lymphoma, prognosis much better in HAART era • CNS Lymphoma-CD4 usually <50, associated with EBV, MRI-irregular enhancing lesions often single by may be multiple usually in periventricular or periependymal areas, thallium SPECT scan helpful

  39. OIs-PRIMARY PROPHYLAXIS • PCP risk: CD4 <200, prior PCP or thrush preferred: TMP-SMX qday alternatives: dapsone 100 mg qday, weekly dapsone/pyrimethamine, aerosolized pentamidine monthly, atovaquone qday immune reconstitution: stop prophylaxis if CD4 >200 for >3 months • TB risk: positive PPD (>5mm) or recent close contact preferred: INH x 9 months

  40. OIs-PRIMARY PROPHYLAXIS • Toxoplasmosis risk: CD4 <100 plus positive Toxo serology preferred: TMP-SMX qday alternatives: dapsone plus pyrimethamine immune reconstitution: stop prophylaxis if CD4 >200 for >3 months •Disseminated MAC risk: CD4 <50 preferred: azithromycin 1200 mg qweek or Biaxin 500 mg BID alternative: rifabutin 300 mg qday immune reconstitution: stop prophylaxis if CD4 >100 for >3 months

More Related